Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The price of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) closed at $15.82 in the last session, down -0.44% from day before closing price of $15.89. In other words, the price has decreased by -$0.44 from its previous closing price. On the day, 0.62 million shares were traded. AUPH stock price reached its highest trading level at $15.88 during the session, while it also had its lowest trading level at $15.64.
Ratios:
We take a closer look at AUPH’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.93 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.32. For the most recent quarter (mrq), Quick Ratio is recorded 5.17 and its Current Ratio is at 5.76. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.17.
On November 07, 2025, Jefferies Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $21.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on November 05, 2025, while the target price for the stock was maintained at $15.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 01 ’25 when TANG KEVIN bought 1,000,000 shares for $10.12 per share. The transaction valued at 10,120,000 led to the insider holds 11,029,500 shares of the business.
TANG KEVIN bought 200,000 shares of AUPH for $2,336,000 on Aug 05 ’25. The Director now owns 11,329,500 shares after completing the transaction at $11.68 per share. On Aug 04 ’25, another insider, TANG KEVIN, who serves as the Director of the company, bought 100,000 shares for $11.34 each. As a result, the insider paid 1,134,000 and bolstered with 11,129,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUPH now has a Market Capitalization of 2085717632 and an Enterprise Value of 1812421632. As of this moment, Aurinia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 28.19, and their Forward P/E ratio for the next fiscal year is 16.92. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.09. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.85 while its Price-to-Book (P/B) ratio in mrq is 5.70. Its current Enterprise Value per Revenue stands at 6.819 whereas that against EBITDA is 18.025.
Stock Price History:
The Beta on a monthly basis for AUPH is 1.47, which has changed by 0.81185865 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, AUPH has reached a high of $16.54, while it has fallen to a 52-week low of $6.55. The 50-Day Moving Average of the stock is 6.47%, while the 200-Day Moving Average is calculated to be 45.17%.
Shares Statistics:
According to the various share statistics, AUPH traded on average about 1.57M shares per day over the past 3-months and 900160 shares per day over the past 10 days. A total of 131.84M shares are outstanding, with a floating share count of 118.08M. Insiders hold about 10.44% of the company’s shares, while institutions hold 53.03% stake in the company. Shares short for AUPH as of 1765756800 were 8393142 with a Short Ratio of 5.34, compared to 1763078400 on 8530321. Therefore, it implies a Short% of Shares Outstanding of 8393142 and a Short% of Float of 6.9699995.
Earnings Estimates
. The current market rating for Aurinia Pharmaceuticals Inc (AUPH) reflects the collective analysis of 6.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.19, with high estimates of $0.22 and low estimates of $0.18.
Analysts are recommending an EPS of between $0.84 and $0.74 for the fiscal current year, implying an average EPS of $0.78. EPS for the following year is $0.94, with 6.0 analysts recommending between $1.33 and $0.64.
Revenue Estimates
According to 7 analysts,. The current quarter’s revenue is expected to be $74.7M. It ranges from a high estimate of $76.61M to a low estimate of $73.26M. As of. The current estimate, Aurinia Pharmaceuticals Inc’s year-ago sales were $59.87MFor the next quarter, 7 analysts are estimating revenue of $75.3M. There is a high estimate of $76.5M for the next quarter, whereas the lowest estimate is $74.4M.
A total of 7 analysts have provided revenue estimates for AUPH’s current fiscal year. The highest revenue estimate was $282.55M, while the lowest revenue estimate was $279.2M, resulting in an average revenue estimate of $280.63M. In the same quarter a year ago, actual revenue was $235.13MBased on 7 analysts’ estimates, the company’s revenue will be $326.8M in the next fiscal year. The high estimate is $359.48M and the low estimate is $302.53M.
